MCC
IOVA icon

Money Concepts Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Money Concepts Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100
Closed -$639 – 1693
2022
Q4 		$639 Hold
100
– – ﹤0.01% 2954
2022
Q3 		$1K Hold
100
– – ﹤0.01% 1468
2022
Q2 		$1K Hold
100
– – ﹤0.01% 1379
2022
Q1 		$2K Buy
+100
New +$1.55K ﹤0.01% 2456

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Money Concepts Capital's IOVA Position: Q1 2023 in Review

Money Concepts Capital sold out of Iovance Biotherapeutics (IOVA) in Q1 2023, closing a stake of 100 shares — an estimated $639 sold.

Money Concepts Capital first reported a position in IOVA in Q1 2022 and held it in 4 quarters. The position peaked at $2K in Q1 2022. 228 funds tracked by Wall St. Rank hold IOVA as of Q1 2023.

  • Money Concepts Capital reported no remaining Iovance Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Money Concepts Capital sold 100 Iovance Biotherapeutics shares in Q1 2023, an estimated $639.
  • Money Concepts Capital first reported a position in Iovance Biotherapeutics in Q1 2022 and held it in 4 quarters.
  • Money Concepts Capital's Iovance Biotherapeutics position peaked at $2K in Q1 2022.
  • 228 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2023.

Based on Money Concepts Capital's 13F filing for Q1 2023, filed 1 May 2023.